Trial Information

Summary: Mild, Moderate, and Severe Kidney Impairment

The purpose of this study is to determine how the investigational medication is absorbed, changed, and removed from the body in volunteers with diabetes and mild, moderate, or severe kidney impairment. Information regarding saftety and side effects will be collected. This study is for research purposes only and is not intended to treat your kidney impairment.

  • Qualified participants will receive study related physical exams, laboratory tests, and compensation up to $2000 for time and travel

To qualify participants must be:

  • 18 to 85 years old
  • Diagnosed with kidney impairment and have diabetes
  • Able to attend two 4 day / 3 night stays in our research dormitory and 13 outpatient visits

Patient Exclusion Criteria:

  • Subjects that have not been diagnosed with kidney disease.

Contact:

Orlando Clinical Research Center
5055 S. Orange Ave.
Orlando, FL 32809
Telephone: 407-240-7876
Email:

Profile Page: Orlando Clinical Research Center, Orlando, FL

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:


Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:32:50 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA